Beta alethine - Dovetail Technologies
Alternative Names: Alethine beta; Ax-101; Beta LT; BetathineLatest Information Update: 28 May 2025
At a glance
- Originator University of New Mexico
- Developer LifeTime Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Lymphoma; Macroglobulinaemia; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 10 Apr 2021 Pharmacodynamics data from a preclinical study in solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 01 Apr 2021 Preclinical trials in Solid tumours in USA (unspecified route), before April 2021